Best GLP-1 Providers in Maryland (2026)

See by medication

Looking for a specific GLP-1? Browse Maryland providers by drug.

About GLP-1s in Maryland

Maryland has a robust telehealth framework supporting GLP-1 prescribing. Maryland Medicaid covers GLP-1s for both diabetes and obesity with prior authorization.

• •Maryland's adult obesity rate is 32.3%
• •Maryland Medicaid covers GLP-1s with prior authorization
• •Telehealth GLP-1 services are widely available statewide

Top Cities for GLP-1 Treatment in Maryland

Telehealth providers ship to all Maryland addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the Maryland GLP-1 clinic directory →

GLP-1 Care Access in Maryland: The Numbers

Maryland has 1,137 NPI-registered in-person weight-management clinics across 121 cities — 16 with an obesity-medicine taxonomy, 605 endocrinology, and 530 bariatric — alongside 97 telehealth programs that ship to Maryland addresses. The cheapest verified ongoing compounded semaglutide price available to Maryland residents is $79/mo (tirzepatide: $97/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in Maryland

In Q1 2026, Maryland Medicaid reimbursed approximately $39,635,931 across 39,587 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in Maryland cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $219/mo.

For the exact criteria, drug list, and appeal process, read our Maryland Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in Maryland

According to CDC data, 32.3% of Maryland adults have obesity (BMI of 30 or higher). This places Maryland at #27 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping Maryland residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions